Strides Pharma Analysis: 2020 Annual Report Takeaways

Reading Time: 4 minutes

Business Overview:

Let’s dig deeper into Strides Pharma Analysis of 2020 Annual Report.

Business Model:

  • Develop and market niche generic formulations across several dosage formats | 124 ANDAs filed (38 pending approval)
    •  Among the world’s leading soft gelatin capsule manufacturers.
  • Debt Repaid during the year: 1374crs | Total debt: 1020crs
    • Weak operating cash flow: 35- 40% conversion (Improving)
    • Capex of 130crs.
  • 5 USFDA approved plants |  8 Manufacturing plants
    • located in India [Bengaluru (two), Puducherry, and Chennai], the US, Singapore, Italy and Kenya.
  • Significantly affected due to withdrawal of all Prescription & OTC Ranitidine drugs from the US market: written off the inventory, and along with the withdrawal cost. Here‘s the timeline:

Existing US Portfolio:

  • 151 products | $23.9B opportunity (FOCUS: Regulated Markets)
    • Expect to file 12-15 ANDAs & approved numbers on similar lines | During the year, filed 4 new ANDAs for the US market and received 7 product approvals.
    • Focus is to grow market share in commercialised products.
    • US FDA approved plant acquired in Florida, USA.
    •  Acquired 18 ANDAs from Pharmaceutics International, Inc. for the US market (US$2.5 Billion market opportunity)

On Puducherry OAI:

“We received a warning letter in July 2019. This event has cast a blemish on our otherwise exemplary track record in having successful outcome from inspections.” ~ Mr Arun Kumar, Founder & Non-executive director

“We now await information from the US FDA on re-inspection. We do not take this lightly. There can be no room for complacency when it comes to quality compliance.” ~ Dr R Ananthanarayanan, MD & CEO

Accepting one’s mistake is a sign of character.

Other Regulated Markets:

    •  Momentum continues in the front-end-led markets of the UK, Australia, South Africa and Canada | 20 new product fillings.
    • Acquired a strategic stake in Fairmed Healthcare AG in Europe, thereby gaining a strong foothold in Germany, Austria and Switzerland (DACH region)
Also Read on FinMedium:  Seven expensive mistakes to avoid while participating in the capital markets

Institutional tender business:

    • Shifted key products in the institutional business from India to our manufacturing site in Nairobi, Kenya, for an ‘In Africa for Africa’ market play. 
  • R&D spend is  3% of sales | 225+ scientists

Strides Pharma Concall Summary by Trendlyne:

Big Development:

  • Announced our re-entry into the sterile injectables segment with an incremental investment of ~US$40 Million in Stelis Biopharma: controls 48% of the company & will increase it to controlling stake.
    •  3 Segments of Stelis: biopharmaceuticals products, Contract Organisation (CDMO) and biologics services and CMO operations for sterile injectables. Paving the growth from FY23 & onwards:
  • Top Investments that have High Future Potential: Consumer Healthcare & Stelis (Invested 90crs in FY20)
  • Segments to focus on global speciality medicines: Oncology, Autoimmune
  • 2608 employees, % increase in median remuneration is -5% while KMP had a high salary increase:
  • Promoter Shareholding: 31.24% | 51% of shares Pledged (expected to go down as the Sequent- Carlyle deal takes place)
  • Institutional shareholders which increased stake; contains the likes of LIC
  • High Contingent liabilities, Although decreasing.
 

Source link

Disclaimer: The opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the FinMedium or its members. The presentation of material therein does not imply the expression of any opinion whatsoever on the part of the FinMedium concerning the legal status of any company, country, area, or territory or of its authorities. For more info. please read our ToU & Privacy Policy here. If you have any concerns regarding this post, please reach out to us at finmedium@gmail.com

Also Read on FinMedium:  BIRLA CORPORATION – Darkhorsestocks

Every Wednesday and Saturday, we send Info-Graphic and FinMedium Weekly Digest newsletters to our 25000+ Subscribers.

Join Them Now!


JST Investments

JST Investments

JST Investments is a Mumbai-based investment firm that believes in long-term wealth creation. It's a brainchild of Aditya Kondawar, Aditya Shah, and Anish Moonka.
Please Share Now :)